Generated $199.7 million in 2Q 2024 revenues, including$179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection)$24.5 million for EMPAVELI® (pegcetacoplan) Initiated a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA); expect a final decision in 4Q 2024 Plan to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in August 2024Cash and cash equivalents of $360.1 million as of June 30, 2024 ...